

H2 47. A pharmaceutical composition containing an anti-human CD23 antibody according to claim 44 and a pharmaceutically acceptable carrier.

48. A chimeric anti-human CD23 antibody wherein the variable light domain comprises the polypeptide encoded by SEQ ID NO: 3 and the variable heavy domain comprises the polypeptide encoded by SEQ ID NO: 4 and a human constant region selected from the group consisting of a human gamma -1 constant region and a human gamma -3 constant region.

49. A chimeric anti-human CD23 antibody wherein the variable light domain comprises the polypeptide encoded by SEQ ID NO: 3 and the variable heavy domain comprises the polypeptide encoded by SEQ ID NO: 4 with the exception that the asparagine colon at position 75 is replaced with a lysine.

50. The anti-human CD23 antibody according to claim 48 which comprises a human gamma -1 constant region.

51. The anti-human CD23 antibody according to claim 48 which comprises a human gamma -3 constant region.

52. The anti-human CD23 antibody according to claim 49 which comprises gamma -1 constant region.

53. The anti-human CD23 antibody according to claim 49 which comprises a human gamma -3 constant region.

54. A pharmaceutical composition comprising an anti-human CD23 antibody according to claim 48 and a pharmaceutically acceptable carrier.

55. A pharmaceutical composition comprising an anti-human CD23 antibody according to claim 49 and a pharmaceutically acceptable carrier.

56. A pharmaceutical composition comprising an anti-human CD23 antibody according to claim 50 and a pharmaceutically acceptable carrier.

57. A pharmaceutical composition comprising an anti-human CD23 antibody according to claim 51 and a pharmaceutically acceptable carrier.

58. A pharmaceutical composition comprising an anti-human CD23 antibody according to claim 52 and a pharmaceutically acceptable carrier.

59. A pharmaceutical composition comprising an anti-human CD23 antibody according to claim 53 and a pharmaceutically acceptable carrier.

60. A pharmaceutical composition comprising an anti-human CD23 antibody according to claim 54 and a pharmaceutically acceptable carrier.